Some ODs have been first approved for diseases with prefixes such as “relapsed,” “refractory,” or “gene-positive” in the target disease name (e.g., “relapsed or refractory multiple myeloma” and “ROS1 fusion gene-positive unresectable advanced or relapsed non-small-cell lung cancer”). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.